Skip to content

Solace European Confirmatory Trial.

An Evaluation of the Solace Bladder Control System in the Treatment of Female Subjects With Stress Urinary Incontinence.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON20657
Enrollment
60
Registered
2013-01-30
Start date
2012-10-31
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stress Urinary Incontinence, SUI, Incontinence

Interventions

Subject will undergo treatment with the Solace Bladder Control System or a sham procedure, with the results being compared at 3 months. All patients undergoing sham treatment are treated at 3 months.

Sponsors

AZM academisch ziekenhuis Maastricht
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Female 18 years of age or older with stress urinary incontinence (SUI); 2. Experienced SUI for at least 12 months and attempted and failed prior noninvasive treatment; 3. Willing to undergo cystoscopic procedures required and 36 month follow-up; 4. On stable medication for a minimum of 3 months; 5. Free of local genital skin infection; 6. Positive Pad Weight Test; 7. Free of impassable urethral strictures, trauma or necrosis.

Exclusion criteria

Exclusion criteria: 1. Pregnant or planning to become pregnant during the study period; 2. Non-ambulatory or bedridden or physically unable to complete test exercises; 3. Morbidly obese (defined as BMI ≥ 40 kg/m2); 4. Bladder infection (including bladder inflammation or edema) or UTI within 3 months; 5. History of recurrent urinary tract infections; 6. Prior surgical procedure for incontinence within the past 6 months; 7. Is taking medications for urinary incontinence other than anticholinergics; 8. History of kidney stones; 9. Has a prosthetic heart valve; 10. Unable to tolerate any form of antibiotic; 11. Taking anticoagulation therapy, other than aspirin; 12. Has urinary incontinence due to Intrinsic Sphincter Deficiency (ISD).

Design outcomes

Primary

MeasureTime frame
Improvement in quality of life as assessed by pad weight tests assessments and questionnaires.

Secondary

MeasureTime frame
1. Incidence of treatment-related adverse events; 2. Severity of treatment-related adverse events.

Contacts

Public ContactK. Weber

Academic Hospital Maastricht

k.weber@mumc.nl+31 (0)43 3876169

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)